02 · Clinical Findings
Menopausal Hormone Therapy May Boost GLP-1 Weight Loss
In a Mayo Clinic study of women 45 and older, pairing semaglutide with hormone therapy led to an 11.6% weight reduction at 15 months versus 9.7% with semaglutide alone.

Pairing semaglutide with hormone therapy yielded an 11.6% weight drop at 15 months among women 45 and older, beating the 9.7% loss from semaglutide alone. Mayo Clinic fellow Regina Castaneda, MD, shared these results from 2,379 semaglutide patients.
Why did the 1,476 tirzepatide users see an added hormone benefit only at month 3 (-6.6% vs -5.9%)? A ceiling effect from tirzepatide's stronger baseline weight loss may leave less room for extra gains.
Prospective trials must still confirm these retrospective data, and weight loss is not an indication for hormone therapy.
Read the full story at MedPage Today ↗
DisclaimerEducational news and research awareness content. Not medical advice.Read full disclaimer ▾
This page shares third-party news coverage, official research listings, and public clinical updates for educational awareness only. Catalyst does not present this information as medical advice, treatment guidance, or a claim of safety, efficacy, or approval.
Related context
How this story connects across the peptide landscape.
Combining two diabetes drug classes is not automatically a bigger clinical benefit

At the highest dose, retatrutide cut 21% of body weight in people with type 2 diabetes

Tirzepatide kept nearly 99% of prediabetes patients diabetes-free over three years

Continue reading · Clinical FindingsPeptide News / Clinical FindingsIncretin Drug May Improve Menstrual RegularityMedPage Today · Nov 2, 2026 · scroll to read